BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. BD has over 70,000 associates serving more than 190 countries, working with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

Collaboration and a mindset of continuous improvement are at the core of BD operations. BD applies lean and continuous improvement methodologies across the enterprise to drive efficiency and cost effectiveness.

PORTFOLIO-WIDE LEADERSHIP COMMITMENTS

50% GHG reduction by 2030
25% reduction in energy intensity by 2030
40% reduction in Water Intensity by 2030

BD IS PARTICIPATING IN THE FOLLOWING DOE PROGRAMS:

BD has made three commitments as a participant in the Better Climate Challenge:

1. They have pledged to reduce GHG emissions by 50% by 2030 (against a 2019 baseline)

2. A 25% energy intensity reduction by 2030 (against a 2019 baseline)

3. Reduce water consumption by 40% by 2030 (against a 2019 baseline)